{"id":968,"date":"2015-12-09T18:25:02","date_gmt":"2015-12-09T18:25:02","guid":{"rendered":"http:\/\/bethechoice.org\/tree\/im-being-tested-for-breast-cancer-now-what\/i-have-breast-cancer-now-what\/information-you-need-to-know\/choose-your-tree\/dcis\/surgery\/mastectomy\/skin-sparing-mastectomy\/skin-nipple-sparing-mastectomy\/hormone-therapy\/"},"modified":"2020-12-02T20:04:13","modified_gmt":"2020-12-03T04:04:13","slug":"hormone-therapy-2-2-2","status":"publish","type":"decision","link":"https:\/\/bethechoice.org\/fr\/tree\/test\/breast-cancer-diagnosed\/decision-trees\/dcis\/surgery-dcis\/lumpectomy-dcis\/lumpectomy-with-sculpting-dcis\/sculpting-other-breast\/radiation-2-2\/delayed-reconstruction\/hormone-therapy-2-2-2\/","title":{"rendered":"Hormonoth\u00e9rapie"},"content":{"rendered":"<p>Dans les cas suivants, l\u2019hormonoth\u00e9rapie est indiqu\u00e9e \u00e0 la suite d\u2019un traitement d\u2019un carcinome canalaire in situ (CCIS) :<\/p>\n<ul>\n<li>CCIS \u00e0 haut risque (haut grade, com\u00e9don\u00e9crose)<\/li>\n<li>CCIS ER\/PR positif<\/li>\n<li>Patient(e) ayant subi une tumorectomie et non une mastectomie<\/li>\n<\/ul>\n<p>L\u2019hormonoth\u00e9rapie est non indiqu\u00e9e pour un CCIS avec caract\u00e9ristiques pl\u00e9omorphiques.<\/p>\n<p>Femmes pr\u00e9m\u00e9nopaus\u00e9es\u00a0: tamoxif\u00e8ne pendant cinq ans<br \/>\nFemmes postm\u00e9nopaus\u00e9es\u00a0: tamoxif\u00e8ne ou inhibiteur de l\u2019aromatase pendant cinq ans<\/p>\n<p>REMARQUE\u00a0: L\u2019hormonoth\u00e9rapie n\u2019am\u00e9liore PAS le taux de survie, mais elle peut diminuer le risque de r\u00e9cidive pour le sein trait\u00e9 ainsi que pour l\u2019autre sein.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans les cas suivants, l\u2019hormonoth\u00e9rapie est indiqu\u00e9e \u00e0 la suite d\u2019un traitement d\u2019un carcinome canalaire in situ (CCIS) : CCIS \u00e0 haut risque (haut grade, com\u00e9don\u00e9crose) CCIS ER\/PR positif Patient(e) ayant subi une tumorectomie et non une mastectomie L\u2019hormonoth\u00e9rapie est non indiqu\u00e9e pour un CCIS avec caract\u00e9ristiques pl\u00e9omorphiques. Femmes pr\u00e9m\u00e9nopaus\u00e9es\u00a0: tamoxif\u00e8ne pendant cinq ans Femmes [&hellip;]<\/p>\n","protected":false},"parent":953,"menu_order":31,"template":"","class_list":["post-968","decision","type-decision","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bethechoice.org\/fr\/wp-json\/wp\/v2\/decision\/968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bethechoice.org\/fr\/wp-json\/wp\/v2\/decision"}],"about":[{"href":"https:\/\/bethechoice.org\/fr\/wp-json\/wp\/v2\/types\/decision"}],"up":[{"embeddable":true,"href":"https:\/\/bethechoice.org\/fr\/wp-json\/wp\/v2\/decision\/953"}],"wp:attachment":[{"href":"https:\/\/bethechoice.org\/fr\/wp-json\/wp\/v2\/media?parent=968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}